Septerna Announces Novel GPCR-targeted Program Acquired by Vertex
Read More
Septerna 250 East Grand Avenue, Suite 65 South San Francisco, CA 94080
Archive for Press Releases
Septerna Bolsters Leadership Team as the Company Advances its Multi-Product Pipeline Toward Clinical Studies
Read More
Septerna Secures $150 Million in Series B Financing to Advance Pipeline of Novel GPCR-targeted Medicines
Read More
Septerna Announces the Formation of a Cross-Functional Scientific and Drug Discovery Advisory Board
Read More
Septerna Appoints Jeffrey Finer, MD, PhD, as Chief Executive Officer
Read More
Septerna Strengthens Leadership Team to Advance Novel Small Molecule GPCR Medicines
Read More
Septerna Launches with $100 Million Series A Financing to Expand the Frontier of GPCR-targeted Medicines using the Native Complex™ Platform
Read More